Want to see GB:CRTX full AI Analyst Report?
Top Page
Amur Minerals
(LSE:CRTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
9.50 p
▼(-17.39% Downside)
Action:Reiterated
Date:09/18/26
The score is driven primarily by weak financial performance (minimal/zero revenue, ongoing losses, and sustained cash burn), supported by bearish technical positioning (price below major moving averages and weak momentum). Valuation provides limited support due to the negative P/E and lack of dividend data.
Positive Factors
Debt-Free Balance Sheet
The absence of financial debt reduces refinancing exposure and avoids interest obligations that could further pressure an exploration company’s cash position. This provides greater balance-sheet flexibility for project work and corporate decisions, although it does not remove the need for external funding.
Negative Factors
No Meaningful Revenue Base
The absence of meaningful recurring revenue leaves the company without an operating sales base to fund exploration, corporate costs, or project development. Revenue falling to zero in 2025 also demonstrates that current financial performance depends on asset progress and financing rather than established commercial operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of financial debt reduces refinancing exposure and avoids interest obligations that could further pressure an exploration company’s cash position. This provides greater balance-sheet flexibility for project work and corporate decisions, although it does not remove the need for external funding.
Read all positive factors
Amur Minerals (CRTX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£7.72M
Dividend Yield765.96%
Average Volume (3M)289.36K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue GrowthN/A
EPS Growth-6.87%
CountryUK
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding79,185,265
10 Day Avg. Volume132,104
30 Day Avg. Volume289,362
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.47
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amur Minerals Business Overview & Revenue Model
Company Description
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumo...
How the Company Makes Money
Amur Minerals’ business model is typical of an exploration-stage mining company: it seeks to create value by acquiring, exploring, delineating, and advancing mineral projects toward development or monetization. For much of its history, the company...
Amur Minerals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 19.98K | 56.88K | 0.00 | 0.00 |
| Gross Profit | -144.00K | -117.00K | 16.78K | -3.79K | 0.00 | 0.00 |
| EBITDA | -2.73M | -2.09M | -452.28K | -2.08M | -1.95M | -1.75M |
| Net Income | -2.39M | -1.90M | -485.05K | -247.74K | -2.45M | -1.54M |
Balance Sheet | ||||||
| Total Assets | 2.92M | 1.80M | 1.82M | 160.53K | 23.89M | 31.24M |
| Cash, Cash Equivalents and Short-Term Investments | 2.27M | 1.13M | 1.28M | 1.26K | 2.90M | 4.93M |
| Total Debt | 0.00 | 0.00 | 0.00 | 496.75K | 0.00 | 0.00 |
| Total Liabilities | 343.00K | 381.00K | 341.00K | 920.19K | 765.65K | 1.13M |
| Stockholders Equity | 2.58M | 1.42M | 1.48M | 4.12M | 23.13M | 30.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.58M | -1.97M | -961.00K | -2.77M | -2.99M | -2.26M |
| Operating Cash Flow | -2.58M | -1.97M | -933.00K | -2.77M | -3.35M | -1.83M |
| Investing Cash Flow | 35.00K | -31.00K | 2.33M | 34.93M | -511.00K | 6.04M |
| Financing Cash Flow | 4.47M | 1.84M | -67.00K | -31.45M | 968.00K | 0.00 |
Amur Minerals Technical Analysis
Negative
11.50
Price Trends
10.39
Negative
10.64
Negative
11.24
Negative
Market Momentum
-0.19
Positive
20.03
Positive
10.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRTX, the sentiment is Negative. The current price of 11.5 is above the 20-day moving average (MA) of 10.97, above the 50-day MA of 10.39, and above the 200-day MA of 11.24, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 20.03 is Positive, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRTX.
Amur Minerals Peers Comparison
UnderperformOutperform
Sector (51)
GB:CRTX
Amur Minerals
9.75
0.25
2.63%
GB:NFX
Nuformix Plc
0.14
0.04
36.89%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.60
-0.15
-8.57%
Amur Minerals Corporate Events
Business Operations and StrategyExecutive/Board Changes
CRISM Therapeutics names seasoned healthcare dealmaker as chair amid Phase 2 trial push
Positive
Sep 17, 2026
CRISM Therapeutics has appointed experienced healthcare executive Dr Charles Spicer as Non-Executive Chair, effective 1 October 2026, with Interim Executive Chairman Andrew Webb returning to his role as chief executive. Spicer’s 25-year trac...
Business Operations and StrategyProduct-Related Announcements
CRISM Therapeutics Starts Phase II ChemoSeed Trial in Glioblastoma
Positive
Aug 20, 2026
CRISM Therapeutics has activated the first clinical site for its Phase II trial of irinotecan ChemoSeed in glioblastoma, marking a key step in moving its lead localised chemotherapy platform into active patient recruitment. The company’s imm...
Business Operations and StrategyProduct-Related Announcements
CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial
Positive
Aug 13, 2026
CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial site in the UK, clearing a key operational step toward starting patient recruitment for its Phase II study in the coming weeks. The trial will test irinoteca...
Business Operations and StrategyRegulatory Filings and Compliance
CRISM Therapeutics Reveals Concentrated Shareholder Base After Register Analysis
Positive
Jul 27, 2026
CRISM Therapeutics Corporation has disclosed the results of an independent shareholder register analysis, identifying investors with holdings of 3% or more of its ordinary share capital as of 30 June 2026. The largest disclosed shareholder is Mito...
Business Operations and StrategyExecutive/Board Changes
CRISM Therapeutics awards long-term share options to executive directors
Positive
Jun 30, 2026
CRISM Therapeutics has granted share options over ordinary shares to three directors under its existing EMI Share Option Plan, with awards reflecting personal performance in 2025 and 2026. The options, all struck at 10 pence, vest in thirds over t...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
CRISM secures key approvals and funding as ChemoSeed platform advances toward Phase 2
Positive
Jun 26, 2026
CRISM Therapeutics is a UK-based clinical-stage oncology company specialising in implantable drug delivery, led by its ChemoSeed platform for the localised and sustained delivery of chemotherapy to solid tumours such as high-grade glioma and prost...
Business Operations and StrategyProduct-Related Announcements
CRISM advances Phase 2 ChemoSeed trial for glioblastoma
Positive
Jun 25, 2026
CRISM Therapeutics said it has completed all manufacturing, quality, regulatory and study start-up work needed to begin treating patients in its Phase 2 trial of irinotecan ChemoSeed for glioblastoma. Clinical site activation is well advanced, wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.